Free Equity Delivery
Flat ₹10 per Trade in Intraday & F&O
| Review By | Apply | May Apply | Neutral | Avoid | Not Rated |
|---|---|---|---|---|---|
| Count | 0 | 0 | 0 | 0 | 0 |
| % | 0 | 0 | 0 | 0 | 0 |
The Captial Market (CapitalMarket.com) rating for Krsnaa Diagnostics IPO is 37. Their analysis recommends Do Not Subscribe for the IPO.
| Reviewer | Rating Score | Rating |
|---|---|---|
| Capital Market | 37 | Do Not Subscribe |
[Dilip Davda] Healthcare sector counters marked hefty gains amidst pandemic scare and currently witnessing some corrections from the higher levels. KDL has posted net profits for FY21 on account of one-time gains and even with these earnings, its issue is aggressively priced at a P/E of 80+ and is thus a costly bet against listed peers. In fact, it has a negative P/E. The segment is highly fragmented with many unorganized players and also having tough competitions from organized players. Considering all these, cash surplus/risk seekers may consider investing in this highly-priced offer, others can avoid. Read detail review...
Krsnaa Diagnostics IPO Reviews, analysis and views by popular members. Read Krsnaa Diagnostics Ltd. IPO reviews by retail investors to find recommended ipo to buy.
| Review By | Apply | May Apply | Neutral | Avoid |
|---|---|---|---|---|
| Count | 0 | 0 | 0 | 0 |
| % | 0.00 | 0.00 | 0.00 | 0.00 |
| Member | Review |
|---|---|
| No recommendation found. Be the first to post the recommendation. | |
Note:
Useful Articles
RHP